The analyst also noted that Benlysta may face competition in the next few years from other drugs in late-stage clinical development, and those potential treatments have the advantage of learning from Benlysta's trial-design shortcomings.
What exactly were Benlysta's trial-design shortcomings and has IMMU incorporated knowledge of such shortcomings into their Phase 3 trials for their lupus drug?